Pharsight

Drugs that contain Eteplirsen

1. Exondys 51 patents expiration

EXONDYS 51's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9416361 SAREPTA THERAPS INC Splice-region antisense composition and method
May, 2021

(3 years ago)

US9018368 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(1 year, 28 days from now)

US10781451 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(1 year, 28 days from now)

US9243245 SAREPTA THERAPS INC Means and methods for counteracting muscle disorders
Oct, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10533174 SAREPTA THERAPS INC Splice-region antisense composition and method
May, 2021

(3 years ago)

US8486907 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(1 year, 28 days from now)

USRE47751 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(1 year, 28 days from now)

USRE48468 SAREPTA THERAPS INC Means and methods for counteracting muscle disorders
Oct, 2028

(4 years from now)

USRE47769 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Feb, 2029

(4 years from now)

US10364431 SAREPTA THERAPS INC Compositions for treating muscular dystrophy
Mar, 2034

(9 years from now)

US10337003 SAREPTA THERAPS INC Compositions for treating muscular dystrophy
Mar, 2034

(9 years from now)

US9506058 SAREPTA THERAPS INC Compositions for treating muscular dystrophy
Mar, 2034

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE) Sep 19, 2023
New Chemical Entity Exclusivity(NCE) Sep 19, 2021
Orphan Drug Exclusivity(ODE-122) Sep 19, 2023

NCE-1 date: 19 September, 2020

Market Authorisation Date: 19 September, 2016

Treatment: (i)treatment of duchenne muscular dystrophy; (ii)restoring/increasing functional dystrophin protein; Or (iii) inducing skipping; Each of (i)-(iii) in patients having a confirmed mutation of the dmd ge...

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

EXONDYS 51 family patents

Family Patents